Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0002 USD | 0.00% | +19,900.00% | -83.33% |
Apr. 12 | Combined Liquidation Plan and Disclosure Statement Filed by Humanigen, Inc. | CI |
Mar. 08 | Final DIP Financing Approved for Humanigen, Inc. | CI |
Financials (USD)
Sales 2021 | 3.6 | Sales 2022 | 2.51 | Capitalization | 14.29M |
---|---|---|---|---|---|
Net income 2021 | -237M | Net income 2022 | -70M | EV / Sales 2021 | 53,517,059 x |
Net cash position 2021 | 45.01M | Net cash position 2022 | 10.16M | EV / Sales 2022 | 1,644,636 x |
P/E ratio 2021 |
-0.92
x | P/E ratio 2022 |
-0.15
x | Employees | 6 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 89.65% |
3 months | +100.00% | ||
6 months | -75.00% | ||
Current year | -83.33% |
Managers | Title | Age | Since |
---|---|---|---|
Cameron Durrant
CEO | Chief Executive Officer | 63 | 16-01-06 |
Omar Ahmed
CTO | Chief Tech/Sci/R&D Officer | - | - |
Dale B. Chappell
CTO | Chief Tech/Sci/R&D Officer | 53 | 20-07-05 |
Members of the board | Title | Age | Since |
---|---|---|---|
Cameron Durrant
CEO | Chief Executive Officer | 63 | 16-01-06 |
Dale B. Chappell
CTO | Chief Tech/Sci/R&D Officer | 53 | 20-07-05 |
Ronald Barliant
BRD | Director/Board Member | 78 | 16-01-06 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.00% | 2 M€ | -.--% |
Date | Price | Change | Volume |
---|---|---|---|
24-05-22 | 0.0002 | 0.00% | 7,350 |
24-05-21 | 0.0002 | 0.00% | 4,439 |
24-05-20 | 0.0002 | +100.00% | 457,748 |
24-05-17 | 0.0001 | -50.00% | 18,407 |
24-05-16 | 0.0002 | +19,900.00% | 12,800 |
Delayed Quote OTC Markets, May 22, 2024 at 11:59 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-83.33% | 23.82K | |
-1.62% | 89.22B | |
+2.24% | 40.49B | |
-15.22% | 32.79B | |
+63.62% | 26.23B | |
-21.82% | 14.52B | |
-7.49% | 13.09B | |
-42.60% | 11.6B | |
-12.64% | 11.5B | |
+5.09% | 8.82B |
- Stock Market
- Equities
- HGENQ Stock